Sign in
Taking people in United StatesPhase 4

Fluciclovine PET scans for prostate cancer that returned after unclear PSMA PET results

Tests fluciclovine PET scans in adults whose prostate cancer may have returned.

Key facts

Who runs it
Blue Earth Diagnostics
Where
Atlanta, Austin, Boston, Portland, San Diego, and St Louis, United StatesSee the 6 sites
Trial code
Registry title
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Status
Recruiting
Phase
Phase 4
People taking part
142 people, planned
Started
31 Aug 2026
Expected to end
31 Dec 2032
Type of study
Interventional
Treatments tested
  • fluciclovine (18F)
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men whose prostate cancer may have come back, shown by a detectable or rising PSA after earlier treatment. Their recent PSMA PET scan was negative or unclear.

Age
18 years or older
Sex
Men only
Disease stage
Suspected return of prostate cancer (biochemical recurrence) shown by PSA after earlier treatment meant to remove all of the disease. After prostate surgery: PSA of 0.2 ng/mL or more, measured more than 6 weeks after surgery. After radiation therapy: PSA at least 2.0 ng/mL above the lowest level, confirmed as rising on repeated tests.
Earlier treatment
Must have had earlier treatment meant to remove all of the disease. Must not have had salvage therapy for this episode of recurrence. Must not have started cancer treatment, or supplements or herbal medicines meant to treat cancer, between the PSMA PET scan and the fluciclovine (18F) PET/CT scan.
Biomarker or test result
A negative or unclear PSMA PET scan with an FDA-approved PSMA PET tracer, done within 45 days before the fluciclovine (18F) PET/CT scan. A detectable or rising PSA.

Main reasons for not taking part

  • Known metastatic castrate resistant prostate cancer
  • Planned X-ray contrast agent or another PET radiotracer within five physical half-lives before the study scan
  • Taking part in another interventional trial within 30 days and having received an investigational product five physical half-lives before the scan
  • Known allergy to fluciclovine (18F) or any of its ingredients
  • Any condition, such as serious uncontrolled infection, that may affect the data or the ability to follow the study

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Participants must be males aged ≥18 years at Screening
  • Participants with suspected BCR of prostate cancer (see Inclusion Criterion #3 below) following prior curative intent treatment and a negative or equivocal PSMA PET scan with any FDA-approved PSMA PET tracer (must be within 45 days prior to Visit 2 [fluciclovine (18F) PET/CT scan]), regardless of findings on conventional imaging
  • Participants suspicious for a biochemically recurrent prostate cancer with a detectable or rising PSA after definitive therapy on the basis of: Post-radical prostatectomy (with or without adjuvant or salvage radiation therapy): PSA that is ≥0.2 ng/mL (completed >6 weeks after surgery) or Post-radiation therapy (with or without ADT): Increase in PSA level that is ≥2.0 ng/mL above the nadir PSA level and rising PSA is confirmed on consecutive PSA determinations
  • Men who are sexually active with women of childbearing potential (WOCBP), must agree to use a highly effective method(s) of contraception for 24 hours post-fluciclovine (18F) injection
  • Participants must provide written informed consent before any study-specific procedures or interventions are performed
  • Ability of the participants to comply with planned study procedures

Who cannot take part

  • Participants with any medical condition (including intercurrent illness and uncontrolled serious infection) or circumstance (including receiving an IP) that the investigator believes may compromise the data collected or lead to a failure to comply with the study requirements
  • Participants who are planned to have an x-ray contrast agent or any other PET radiotracer within five physical half-lives of the first PET radionuclide prior to the study fluciclovine (18F) PET/CT scan
  • Participants participating in an interventional clinical trial within 30 days and having received an IP five physical half-lives prior to the study fluciclovine (18F) PET/CT scan
  • Participants who have received salvage therapy for the current episode of BCR
  • Participants with known metastatic castrate resistant prostate cancer
  • Participants with known hypersensitivity to the active substance or to any of the excipients of fluciclovine (18F)
  • Participants who initiate cancer treatment (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the PSMA PET and fluciclovine (18F) PET/CT scans

Where in United States

  • Emory UniversityAtlanta, United StatesContact: Ismaheel Lawal, MDTaking people
  • Urology AustinAustin, United StatesContact: Brian Mazzarella, MDTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Pedram Heidari, MDTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Nadine Mallak, MDTaking people
  • University of California San Diego HealthSan Diego, United StatesContact: Sherief H Gamie, MDNot yet recruiting
  • Washington UniversitySt Louis, United StatesContact: Ashwin Parihar, MDNot yet recruiting

About the trial

What the trial wants to find out

The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

The group in the trial

  • Patients Single intravenous administration of fluciclovine (18F) for PET ScanTreatment being tested

    Treatment: fluciclovine (18F)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Fluciclovine (18F) PET on the Management of Participants With Prostate Cancer Following Negative or Equivocal PSMA PET Imaging at the Time of Biochemical Recurrence
Plain-language title
Fluciclovine PET scans for prostate cancer that returned after unclear PSMA PET resultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 November 2026